GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Macrogenics Inc (FRA:M55) » Definitions » Cash Payments for Deposits by Banks and Customers

Macrogenics (FRA:M55) Cash Payments for Deposits by Banks and Customers


View and export this data going back to 2013. Start your Free Trial

What is Macrogenics Cash Payments for Deposits by Banks and Customers?

Cash Payments for Deposits by Banks and Customers only applicable to companies reporting Cash Flow from Operations in direct method.


Macrogenics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Macrogenics Inc (FRA:M55) » Definitions » Cash Payments for Deposits by Banks and Customers
Traded in Other Exchanges
Address
9704 Medical Center Drive, Rockville, MD, USA, 20850
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.